ArticleMolecular biology reports2025
Selenium and resveratrol attenuate rotenone-induced Parkinson's disease in zebrafish model.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Gramicidin A attenuates oxidative stress, mitochondrial dysfunction, DNA damage, and inflammation in 6-OHDA-induced SH-SY5Y cells.Molecular biology reports · 2026Article
- Resveratrol and the neuroinflammation axis in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and cerebral ischemia.Frontiers in immunology · 2026Review
- The Role of Vitamin D in Parkinson's Disease: Evidence from Serum Concentrations, Supplementation, andNeuroSci · 2025Review
- Astrocytic and microglial cell functions in neuroinflammatory diseases and their animal models.Frontiers in cellular neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
abractstBACKGROUND AND
aimsParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons, leading to motor and non-motor symptoms. Oxidative stress and inflammation are key contributors to PD pathogenesis, yet current treatments primarily focus on dopamine replacement and fail to address these underlying mechanisms. This study investigates the neuroprotective potential of a combination of five compounds-N-acetylcysteine (NAC), resveratrol, quercetin, selenium, and coenzyme Q10 (CoQ10)-in a zebrafish model of PD induced by rotenone.
methodsEighty adult male zebrafishes were divided into eight groups, including control, rotenone-only, and groups treated with individual compounds or the combination (2QRNS). Motor activity, dopamine levels, and expression of genes related to oxidative stress, apoptosis, autophagy, and inflammation were assessed.
resultsResults showed that rotenone significantly reduced motor activity and dopamine levels, while the 2QRNS cocktail, selenium, and resveratrol were most effective in mitigating these effects. Selenium notably enhanced the expression of antioxidant genes (superoxide dismutase and glutathione peroxidase) and inhibited apoptosis and autophagy pathways. Resveratrol demonstrated strong anti-inflammatory effects by reducing interleukin-6 (IL-6) expression.
conclusionThese findings suggest that the 2QRNS combination, particularly selenium and resveratrol, offers significant neuroprotection in a PD model by targeting oxidative stress, inflammation, and cell death pathways. Further studies on other PD models and detailed molecular pathways are recommended to validate these results and explore their clinical potential.
Indexed as
Identifiers
40794323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.